-
Pliant Stock Moves Higher On Positive Data From Pulmonary Fibrosis Trial
Tuesday, September 7, 2021 - 7:21am | 220Read More...Pliant Therapeutics Inc (NASDAQ: PLRX) stock is moving higher during the premarket session in reaction to interim results from a Phase 2a positron emission tomography (PET) imaging-based trial of PLN-74809 for idiopathic pulmonary fibrosis (IPF). PLN-74809 is an oral small molecule...
-
Pieris Stock Moves Higher On €14.2M Grant For PRS-220 In Post-COVID Pulmonary Fibrosis
Friday, June 25, 2021 - 9:18am | 156Read More...Pieris Pharmaceuticals Inc (NASDAQ: PIRS) has announced the development of PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor to treat idiopathic pulmonary fibrosis (IPF). The Company will also receive a €14.2 million (approximately $17...
-
Protalix BioTherapeutics Perks Up On Alidornase Alfa Licensing Pact In Respiratory Conditions
Thursday, February 11, 2021 - 8:47am | 259Read More...Protalix BioTherapeutics Inc (NYSE: PLX) has announced an exclusive worldwide license agreement with SarcoMed USA Inc for alidornase alfa, also known as PRX–110, for use in the treatment of any human respiratory disease or condition including, sarcoidosis, pulmonary...
-
Galapagos, Gilead Sciences Pull Plug On Ziritaxestat Clinical Trials
Wednesday, February 10, 2021 - 12:10pm | 449Read More...Galapagos NV (NASDAQ: GLPG) and Gilead Sciences Inc (NASDAQ: GILD) have decided to stop the ISABELA Phase 3 studies evaluating ziritaxestat in patients with idiopathic pulmonary fibrosis (IPF). All clinical trials with ziritaxestat, including the long-term...
